Wednesday, October 15, 2008

ZIOPHARM Receives Orphan Medicinal Product Designation for Palifosfamide (ZIO-201) in the Treatment of Soft Tissue Sarcoma

Oct 15, 2008 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today that the European Medicines Agency's (EMEA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion regarding ZIOPHARM's application for orphan medicinal product designation for palifosfamide in the treatment of soft tissue sarcoma (STS).

The details can be read here.

No comments: